1541-7786
Monthly
No
MOL CANCER RES
2002
161
UNITED STATES
偏慢,4-8周審稿時間
較易平均錄用比例
4.484影響因子
細胞生物學小學科
月期刊平臺服務過的文章錄用時間為1-3個月,依據(jù)20年經(jīng)驗,經(jīng)月期刊專家預審通過后的文章,投稿通過率100%以上!
分子癌癥研究發(fā)表文章描述了對該領域有廣泛興趣的新的基礎癌癥研究發(fā)現(xiàn)。研究必須具有證明意義,并且該雜志將分子和細胞水平的分析放在首位,揭示了與癌癥風險、發(fā)展和/或進展相關的途徑和過程的新的機械洞察。重點領域包括所有癌癥相關途徑(包括細胞周期調節(jié)、細胞死亡、染色質調節(jié)、DNA損傷和修復、基因和RNA調節(jié)、基因組學、癌基因和腫瘤抑制因子以及信號轉導),以及描述支持癌癥表型的新分子機制和相互作用的研究。為了充分考慮,提交的初步研究必須提供對現(xiàn)有通路功能的重要新見解,或解決與癌癥相關的生物學問題相關的新假設。分子癌癥研究接受提交的初步研究,評論和評論文章類型以及給編輯的信件。有關提交給作者的文章類型的描述和長度要求,請參閱分子癌癥研究的文章類別。AACR期刊都使用類似的編輯過程。請注意,分子癌癥研究不考慮上訴。提交作者必須熟悉AACR期刊的編輯政策,包括關于作者身份、出版道德、材料和數(shù)據(jù)的可用性以及數(shù)據(jù)分析和報告的重要信息。對手稿進行嚴格的審查,以獲得高標準的科學價值,只有那些報告小說、及時和廣泛重要研究成果的手稿才被接受出版。
http://mcr.msubmit.net/cgi-bin/main.plex
Molecular Cancer Research publishes articles describing novel basic cancer research discoveries of broad interest to the field. Studies must be of demonstrated significance, and the journal prioritizes analyses performed at the molecular and cellular level that reveal novel mechanistic insight into pathways and processes linked to cancer risk, development, and/or progression. Areas of emphasis include all cancer-associated pathways (including cell-cycle regulation; cell death; chromatin regulation; DNA damage and repair; gene and RNA regulation; genomics; oncogenes and tumor suppressors; and signal transduction), in addition to studies describing new molecular mechanisms and interactions that support cancer phenotypes. For full consideration, primary research submissions must provide significant novel insight into existing pathway functions or address new hypotheses associated with cancer-relevant biologic questions.Molecular Cancer Research accepts submissions of primary research, review and commentary article types as well as letters to the editor. For descriptions and length requirements of the article types available to submitting authors see the Categories of Articles for Molecular Cancer Research. The AACR Journals all use a similar Editorial Process. Please note that Molecular Cancer Research does not consider appeals.Submitting authors must be familiar with the Editorial Policies of the AACR Journals covering important information on authorship, publishing ethics, availability of materials and data and data analysis and reporting.Manuscripts are stringently reviewed for high standards of scientific merit, and only those that report results of novel, timely, and broadly-significant research are accepted for publication.
快速預審、投刊前指導、專業(yè)學術評審,對文章進行評價;
立即咨詢校對編輯、深度潤色,讓稿件符合學術規(guī)范,格式體例等標準;
立即咨詢適用于語句和結構尚需完善和調整的中文文章,確保稿件達到要求;
立即咨詢數(shù)據(jù)庫包括:期刊、文章、書籍、會議、預印書、百科全書和摘要等;
立即咨詢讓作者在期刊選擇時避免走彎路,縮短稿件被接收的周期;
立即咨詢根據(jù)目標期刊格式要求對作者文章進行全面的格式修改和調整;
立即咨詢幫助作者將稿件提交至目標期刊投稿系統(tǒng),降低退稿或拒稿率;
立即咨詢按照您提供的稿件內容,指導完成投稿附信(cover letter);
立即咨詢大類學科同領域優(yōu)質期刊 | 大類學科 | 小類學科 | 影響因子 | 分區(qū) | ISSN |
---|---|---|---|---|---|
AGEING RESEARCH REVIEWS | 醫(yī)學 | 細胞生物學 | 10.39 | N/A | 1568-1637 |
Analytical and Quantitative Cytopathology and Histopathology | 醫(yī)學 | 細胞生物學 | 0.185 | N/A | 0884-6812 |
CANCER CELL | 醫(yī)學 | 細胞生物學 | 23.916 | N/A | 1535-6108 |
CELL AND TISSUE BANKING | 醫(yī)學 | 細胞生物學 | 1.939 | N/A | 1389-9333 |
Disease Models & Mechanisms | 醫(yī)學 | 細胞生物學 | 4.028 | N/A | 1754-8403 |
EXPERIMENTAL CELL RESEARCH | 醫(yī)學 | 細胞生物學 | 3.329 | N/A | 0014-4827 |
GROWTH HORMONE & IGF RESEARCH | 醫(yī)學 | 細胞生物學 | 2.167 | N/A | 1096-6374 |
HISTOPATHOLOGY | 醫(yī)學 | 細胞生物學 | 3.294 | 3區(qū) | 0309-0167 |
IMMUNOLOGY AND CELL BIOLOGY | 醫(yī)學 | 細胞生物學 | 3.947 | N/A | 0818-9641 |
INFLAMMATION | 醫(yī)學 | 細胞生物學 | 2.939 | 3區(qū) | 0360-3997 |
發(fā)現(xiàn)心儀選題請?zhí)顔?/b>
獲取發(fā)表周期短、審稿速度快容易錄用的期刊